vaccinex
announces
clinical
collaboration
merck
evaluate
pepinemab
combination
advanced
recurrent
metastatic
head
neck
squamous
cell
carcinoma
rochester
globe
newswire
vaccinex
nasdaq
vcnx
biotechnology
company
pioneering
novel
approach
treating
cancer
neurodegenerative
disease
inhibition
today
announced
entered
clinical
collaboration
agreement
merck
known
msd
outside
us
canada
subsidiary
evaluate
combination
vaccinex
investigational
inhibitor
pepinemab
merck
therapy
pembrolizumab
treatment
patients
advanced
recurrent
metastatic
head
neck
squamous
cell
carcinoma
hnscc
pleased
working
merck
evaluate
potential
pepinemab
combination
improve
efficacy
cancer
immunotherapy
said
maurice
zauderer
president
chief
executive
officer
vaccinex
several
prior
studies
suggest
inhibition
increases
immune
infiltration
alters
balance
cytotoxic
immunosuppressive
cells
tumor
microenvironment
highly
expressed
hnscc
believed
promote
correspondingly
high
levels
myeloid
derived
suppressor
cells
collaboration
provides
opportunity
evaluate
innovative
approach
combination
planned
clinical
collaboration
pepinemab
pembrolizumab
consist
dose
escalation
phase
followed
expansion
phase
enroll
hnscc
patients
allocated
different
levels
combined
positive
score
cps
expression
cps
biomarker
associated
benefit
response
immunotherapy
major
goal
study
determine
whether
combination
therapy
improve
response
populations
key
endpoints
study
include
objective
response
progression
free
survival
overall
survival
registered
trademark
merck
sharp
dohme
subsidiary
merck
kenilworth
nj
usa
pepinemab
pepinemab
also
known
humanized
monoclonal
antibody
binds
blocks
activity
semaphorin
extracellular
signaling
molecule
regulates
migration
function
immune
inflammatory
cells
preclinical
studies
demonstrated
biological
activities
associated
antibody
blockade
promote
immune
cell
infiltration
tumors
prevent
neurological
damage
neuroinflammatory
neurodegenerative
disease
models
vaccinex
focused
development
pepinemab
treatment
cancer
neurodegenerative
diseases
including
huntington
disease
pepinemab
investigational
new
drug
yet
approved
food
drug
administration
fda
regulatory
authorities
indication
vaccinex
vaccinex
pioneering
differentiated
approach
treating
cancer
neurodegenerative
disease
inhibition
semaphorin
key
driver
immune
infiltration
neuroinflammation
company
lead
drug
candidate
pepinemab
blocks
potential
immune
enhancing
therapy
cancer
treatment
huntington
alzheimer
neurodegenerative
diseases
company
additionally
intends
leverage
proprietary
drug
discovery
platform
create
opportunities
future
pipeline
expansion
strategic
collaborations
forward
looking
statements
extent
statements
contained
press
release
descriptions
historical
facts
regarding
vaccinex
vaccinex
us
statements
reflecting
management
current
beliefs
expectations
statements
include
limited
statements
plans
expectations
objectives
respect
huntington
alzheimer
disease
cancer
clinical
trials
use
pepinemab
statements
identified
words
may
appears
expect
anticipate
estimate
intend
hypothesis
potential
advance
similar
expressions
negatives
well
words
expressions
referencing
future
events
conditions
circumstances
statements
involve
substantial
risks
uncertainties
could
cause
research
development
programs
clinical
development
programs
future
results
performance
achievements
differ
significantly
expressed
implied
statements
risks
uncertainties
include
among
others
uncertainties
inherent
execution
cost
completion
preclinical
clinical
trials
uncertainties
related
regulatory
approval
uncertainties
respect
whether
fda
agree
signal
trial
qualifies
pivotal
trial
risks
related
dependence
lead
product
candidate
pepinemab
matters
could
affect
development
plans
commercial
potential
product
candidates
except
required
law
assume
obligation
update
statements
discussion
factors
could
cause
future
results
differ
materially
statement
see
section
titled
risk
factors
periodic
reports
filed
securities
exchange
commission
sec
risks
uncertainties
described
form
dated
march
subsequent
filings
sec
investor
contact
jeremyfeffer
lifesci
advisors
llc
jeremy
